{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:41:11Z","timestamp":1792428071320,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the National Natural Science Foundation of China","award":["82303764"],"award-info":[{"award-number":["82303764"]}]},{"DOI":"10.13039\/501100010031","name":"Postdoctoral Research Foundation of China","doi-asserted-by":"publisher","award":["2023M740616"],"award-info":[{"award-number":["2023M740616"]}],"id":[{"id":"10.13039\/501100010031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025T180583"],"award-info":[{"award-number":["2025T180583"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young Elite Scientists Sponsorship Program by Jiangsu Association for Science and Technology","award":["JSTJ-2025-502"],"award-info":[{"award-number":["JSTJ-2025-502"]}]},{"name":"the High-level Hospital Talent Construction","award":["CZXM-GSP-RC03"],"award-info":[{"award-number":["CZXM-GSP-RC03"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-Young2024-0102"],"award-info":[{"award-number":["Y-Young2024-0102"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08672-3","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:04:57Z","timestamp":1784646297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TCM-derived immunometabolic modulators as systems adjuvants for CAR-T therapy in solid tumors: evidence hierarchy and translational roadmap"],"prefix":"10.1186","volume":"24","author":[{"given":"Fei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6943-2624","authenticated-orcid":false,"given":"Feng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"1","key":"8672_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM. CAR t cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21(1):47\u201366.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"8672_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, et al. CAR-t cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10(1):210.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"8672_CR3","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-t therapy in solid tumors. Cancer Cell. 2025;43(4):665\u201379.","journal-title":"Cancer Cell"},{"issue":"5","key":"8672_CR4","first-page":"101028","volume":"7","author":"R Rosa","year":"2026","unstructured":"Rosa R, Liu J, Lu C, Abou-El-Enein M, Murad JP, Priceman SJ. Current state of CAR-t cell therapies for solid tumors. Med (N Y). 2026;7(5):101028.","journal-title":"Med (N Y)"},{"issue":"10494","key":"8672_CR5","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi C, Liu C, Peng Z, Zhang Y, Wei J, Qiu W, et al. Claudin-18 isoform 2-specific CAR t-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet (London England). 2025;405(10494):2049\u201360.","journal-title":"Lancet (London England)"},{"issue":"4","key":"8672_CR6","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s41591-025-03499-9","volume":"31","author":"T Braun","year":"2025","unstructured":"Braun T, Rade M, Merz M, Klepzig H, Gro\u00dfe F, Fandrei D, et al. Multiomic profiling of t cell lymphoma after therapy with anti-BCMA CAR t cells and GPRC5d-directed bispecific antibody. Nat Med. 2025;31(4):1145\u201353.","journal-title":"Nat Med"},{"issue":"14","key":"8672_CR7","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, et al. Intraventricular CARv3-TEAM-e t cells in recurrent glioblastoma. N Engl J Med. 2024;390(14):1290\u20138.","journal-title":"N Engl J Med"},{"issue":"5","key":"8672_CR8","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, et al. Intrathecal bivalent CAR t cells targeting EGFR and IL13r\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat Med. 2024;30(5):1320\u20139.","journal-title":"Nat Med"},{"issue":"3","key":"8672_CR9","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza NA, Ronsley R, Choe M, Seidel K, Huang W, Rawlings-Rhea SD, et al. Intracerebroventricular b7-h3-targeting CAR t cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat Med. 2025;31(3):861\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"8672_CR10","doi-asserted-by":"publisher","first-page":"9914","DOI":"10.1038\/s41467-025-64861-6","volume":"16","author":"EZ Song","year":"2025","unstructured":"Song EZ, Timpanaro A, Meechan M, Elena-Sanchez L, Li LZ, Jamet S, et al. Engineered CXCR3-a expression enhances b7-h3-targeting CAR t cell migration and efficacy against diffuse intrinsic pontine glioma. Nat Commun. 2025;16(1):9914.","journal-title":"Nat Commun"},{"key":"8672_CR11","first-page":"211","volume-title":"Probiotic-guided CAR-t cells for solid tumor targeting","author":"RL Vincent","year":"2023","unstructured":"Vincent RL, Gurbatri CR, Li F, Vardoshvili A, Coker C, Im J, et al. Probiotic-guided CAR-t cells for solid tumor targeting. Volume 382. New York, N.Y.: Science; 2023. pp. 211\u20138. 6667."},{"issue":"4","key":"8672_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41551-025-01509-2","volume":"10","author":"JP Murad","year":"2026","unstructured":"Murad JP, Christian L, Rosa R, Ren Y, Buckley AJ, Lee EHJ, et al. Solid tumour CAR-t cells engineered with fusion proteins targeting PD-l1 for localized IL-12 delivery. Nat Biomed Eng. 2026;10(4):613\u201329.","journal-title":"Nat Biomed Eng"},{"issue":"8075","key":"8672_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41586-025-09212-7","volume":"644","author":"AXY Chen","year":"2025","unstructured":"Chen AXY, Yap KM, Kim JS, Sek K, Huang Y, Dunbar PA, et al. Rewiring endogenous genes in CAR t cells for tumour-restricted payload delivery. Nature. 2025;644(8075):241\u201351.","journal-title":"Nature"},{"issue":"1","key":"8672_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.","journal-title":"Mol Cancer"},{"issue":"7","key":"8672_CR15","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1039\/D3NR05768B","volume":"16","author":"Y Lin","year":"2024","unstructured":"Lin Y, Chen Y, Luo Z, Wu Y. Recent advances in biomaterial designs for assisting CAR-t cell therapy towards potential solid tumor treatment. Nanoscale. 2024;16(7):3226\u201342.","journal-title":"Nanoscale"},{"issue":"1","key":"8672_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41419-025-07454-x","volume":"16","author":"Z Wang","year":"2025","unstructured":"Wang Z, Li P, Zeng X, Guo J, Zhang C, Fan Z, et al. CAR-t therapy dilemma and innovative design strategies for next generation. Cell Death Dis. 2025;16(1):211.","journal-title":"Cell Death Dis"},{"issue":"1","key":"8672_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12943-024-02213-6","volume":"24","author":"S Li","year":"2025","unstructured":"Li S, Chen X, Shi H, Yi M, Xiong B, Li T. Tailoring traditional chinese medicine in cancer therapy. Mol Cancer. 2025;24(1):27.","journal-title":"Mol Cancer"},{"issue":"1","key":"8672_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","volume":"10","author":"J Xu","year":"2025","unstructured":"Xu J, Ding L, Mei J, Hu Y, Kong X, Dai S, et al. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target Ther. 2025;10(1):268.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"8672_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1186\/s12917-025-05045-8","volume":"21","author":"LV Muscatello","year":"2025","unstructured":"Muscatello LV, D\u2019Annunzio G, Franceschini T, Tugnoli C, Grillini A, Bacci B, et al. Tumor immune microenvironment and immune phenotypes in PD-l1-tested canine urothelial carcinoma. BMC Vet Res. 2025;21(1):681.","journal-title":"BMC Vet Res"},{"issue":"1","key":"8672_CR20","doi-asserted-by":"publisher","first-page":"6858","DOI":"10.1038\/s41467-023-42634-3","volume":"14","author":"H Wu","year":"2023","unstructured":"Wu H, Zhao X, Hochrein SM, Eckstein M, Gubert GF, Kn\u00f6pper K, et al. Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted t cells through HIF-1\u03b1-mediated glycolytic reprogramming. Nat Commun. 2023;14(1):6858.","journal-title":"Nat Commun"},{"key":"8672_CR21","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber D, Wang LD. Improving CAR-t immunotherapy: overcoming the challenges of t cell exhaustion. EBioMedicine. 2022;77:103941.","journal-title":"EBioMedicine"},{"key":"8672_CR22","doi-asserted-by":"publisher","first-page":"1662145","DOI":"10.3389\/fimmu.2025.1662145","volume":"16","author":"G Li","year":"2025","unstructured":"Li G, Li D, Zhu X. Next-generation t cell immunotherapy: overcoming exhaustion, senescence, and suppression. Front Immunol. 2025;16:1662145.","journal-title":"Front Immunol"},{"issue":"1","key":"8672_CR23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1186\/s12967-025-06606-z","volume":"23","author":"B Park","year":"2025","unstructured":"Park B, Kim J, Baylink DJ, Hino C, Kwon C, Tran V, et al. Nutrient-gene therapy as a strategy to enhance CAR t cell function and overcome barriers in the tumor microenvironment. J Transl Med. 2025;23(1):633.","journal-title":"J Transl Med"},{"issue":"1","key":"8672_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41419-025-08405-2","volume":"17","author":"Y Pang","year":"2025","unstructured":"Pang Y, Chen L, Sun Q, He N, Lai Z, Wang X, et al. A new strategy for CAR-t therapy in solid tumors: IL-15-autocrine signaling augments tumor stroma depletion and promotes a t(SCM) subset in the TME. Cell Death Dis. 2025;17(1):39.","journal-title":"Cell Death Dis"},{"key":"8672_CR25","doi-asserted-by":"publisher","first-page":"1095186","DOI":"10.3389\/fphar.2022.1095186","volume":"13","author":"W Lam","year":"2023","unstructured":"Lam W, Hu R, Liu S, Cheng P, Cheng Y. YIV-906 enhances nuclear factor of activated t-cells (NFAT) activity of t cells and promotes immune checkpoint blockade antibody action and CAR t-cell activity. Front Pharmacol. 2023;13:1095186.","journal-title":"Front Pharmacol"},{"key":"8672_CR26","doi-asserted-by":"crossref","unstructured":"Zhang Q, Su C, Luo Y, Zheng F, Liang C, Chen Y, et al. Astragalus polysaccharide enhances antitumoral effects of chimeric antigen receptor- engineered (CAR) t cells by increasing CD122(+)CXCR3(+)PD-1(-) memory t cells. Biomed Pharmacother. 2024;179:117401.","DOI":"10.1016\/j.biopha.2024.117401"},{"issue":"3","key":"8672_CR27","first-page":"170","volume":"5","author":"Y Liu","year":"2023","unstructured":"Liu Y, An L, Yang C, Wang X, Huang R, Zhang X. Ginsenoside rg1 improves anti-tumor efficacy of adoptive cell therapy by enhancing t cell effector functions. Blood Sci. 2023;5(3):170\u20139.","journal-title":"Blood Sci"},{"issue":"4","key":"8672_CR28","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3390\/antiox14040454","volume":"14","author":"P Limsakul","year":"2025","unstructured":"Limsakul P, Srifa P, Huang Z, Zhu L, Wu Y, Charupanit K. Immunomodulatory effects of curcumin on CAR t-cell therapy. Antioxid (Basel). 2025;14(4):454.","journal-title":"Antioxid (Basel)"},{"key":"8672_CR29","doi-asserted-by":"crossref","unstructured":"Duan J, Xue Y, Zhang M, Zhang Z, Peng S, Sui M et al. Ultrasmall fe-curcumin immunomodulators reinvigorate CAR\u2010t cells to potentiate solid tumor immunotherapy by mitigating cell exhaustion and senescence. BMEMat. 2026.","DOI":"10.1002\/bmm2.70078"},{"issue":"1","key":"8672_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13045-021-01168-1","volume":"14","author":"F Ji","year":"2021","unstructured":"Ji F, Zhang F, Zhang M, Long K, Xia M, Lu F, et al. Targeting the DNA damage response enhances CD70 CAR-t cell therapy for renal carcinoma by activating the cGAS-STING pathway. J Hematol Oncol. 2021;14(1):5.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"8672_CR31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12951-025-03336-8","volume":"23","author":"S Ma","year":"2025","unstructured":"Ma S, Zhang X, Zhu X, Yan K, Wang Q, Lei L, et al. Dual-modality immune nano-activator harnessing mn(2)\u207a and quercetin to potentiate the cGAS-STING pathway for advanced cancer metalloimmunotherapy. J Nanobiotechnol. 2025;23(1):248.","journal-title":"J Nanobiotechnol"},{"key":"8672_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2023.03.003","volume":"259","author":"F Ji","year":"2023","unstructured":"Ji F, Xu L, Long K, Zhang F, Zhang M, Lu X, et al. Rabies virus glycoprotein 29 (RVG29) promotes CAR-t immunotherapy for glioma. Transl Res. 2023;259:1\u201312.","journal-title":"Transl Res"},{"key":"8672_CR33","doi-asserted-by":"crossref","unstructured":"Ji F, Gao K, Wu X, Lin H. Genomic characterization of rabies virus glycoprotein co-expressing CD70 CAR-t cells during killing of glioma cells in vitro. Front Immunol. 2026;17.","DOI":"10.3389\/fimmu.2026.1680513"},{"issue":"3","key":"8672_CR34","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41388-025-03663-y","volume":"45","author":"F Ji","year":"2026","unstructured":"Ji F, Yan K, Ding B, Zhu Y, Rao M, Gao K, et al. Dual-target CAR-t therapy for ovarian cancer: synergistic targeting of MSLN and b7h3 enhances anti-tumor efficacy and overcomes antigen heterogeneity. Oncogene. 2026;45(3):446\u201358.","journal-title":"Oncogene"},{"key":"8672_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.intimp.2025.114919","volume":"159","author":"F Ji","year":"2025","unstructured":"Ji F, Yu J, Zhu Y, Lin H, Gao K, Rao M, et al. B4m3 CAR-t cell enhance antitumor activity and non-tumor toxicity in ovarian cancer. Int Immunopharmacol. 2025;159:11.","journal-title":"Int Immunopharmacol"},{"key":"8672_CR36","doi-asserted-by":"crossref","unstructured":"Shan Y, Ding B, Ji F, Lin H, Shi W, Wang E, et al. T-cell receptor\u2013like chimeric antigen receptor t cells targeting mesothelin: a first\u2010in\u2010human dose\u2010escalation trial for platinum\u2010resistant advanced ovarian cancer. Cancer 2026;132(3).","DOI":"10.1002\/cncr.70279"},{"issue":"5","key":"8672_CR37","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.eng.2019.01.015","volume":"5","author":"Y Li","year":"2019","unstructured":"Li Y, Xie Y, He Y, Hou W, Liao M, Liu C. Quality markers of traditional chinese medicine: concept, progress, and perspective. Engineering. 2019;5(5):888\u201394.","journal-title":"Engineering"},{"key":"8672_CR38","doi-asserted-by":"crossref","unstructured":"Thikar D, Naik GG, Jagtap VA. Quality control of traditional chinese medicinal formulations. Chem Zvesti. 2025.","DOI":"10.1007\/s11696-025-04548-w"},{"issue":"Pt 2","key":"8672_CR39","doi-asserted-by":"publisher","first-page":"149726","DOI":"10.1016\/j.ijbiomac.2025.149726","volume":"339","author":"Y Yin","year":"2026","unstructured":"Yin Y, Wei X, Song Y, Zhuang J, Liu L, Liu Y, et al. Quality evaluation of astragalus membranaceus based on polysaccharide fingerprinting and chemometric analysis. Int J Biol Macromol. 2026;339(Pt 2):149726.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"8672_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-025-02311-x","volume":"10","author":"H Du","year":"2025","unstructured":"Du H, Xu T, Yu S, Wu S, Zhang J. Mitochondrial metabolism and cancer therapeutic innovation. Signal Transduct Target Ther. 2025;10(1):245.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"8672_CR41","doi-asserted-by":"publisher","first-page":"102021","DOI":"10.1016\/j.xcrm.2025.102021","volume":"6","author":"A Akhtar","year":"2025","unstructured":"Akhtar A, Shakir M, Ansari MS, Divya, Faizan MI, Chauhan V, et al. Bioengineering the metabolic network of CAR t cells with GLP-1 and urolithin a increases persistence and long-term anti-tumor activity. Cell Rep Med. 2025;6(3):102021.","journal-title":"Cell Rep Med"},{"issue":"9","key":"8672_CR42","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41577-025-01161-6","volume":"25","author":"L Galluzzi","year":"2025","unstructured":"Galluzzi L, Smith KN, Liston A, Garg AD. The diversity of CD8(+) t cell dysfunction in cancer and viral infection. Nat Rev Immunol. 2025;25(9):662\u201379.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"8672_CR43","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/15548627.2024.2439657","volume":"21","author":"B Hao","year":"2025","unstructured":"Hao B, Lin S, Liu H, Xu J, Chen L, Zheng T, et al. Baicalein tethers CD274\/PD-l1 for autophagic degradation to boost antitumor immunity. Autophagy. 2025;21(5):917\u201333.","journal-title":"Autophagy"},{"key":"8672_CR44","doi-asserted-by":"publisher","first-page":"107032","DOI":"10.1016\/j.phrs.2023.107032","volume":"199","author":"R Wang","year":"2024","unstructured":"Wang R, Wang C, Lu L, Yuan F, He F. Baicalin and baicalein in modulating tumor microenvironment for cancer treatment: a comprehensive review with future perspectives. Pharmacol Res. 2024;199:107032.","journal-title":"Pharmacol Res"},{"issue":"19","key":"8672_CR45","doi-asserted-by":"publisher","first-page":"19770","DOI":"10.1021\/acsomega.5c00981","volume":"10","author":"P Yang","year":"2025","unstructured":"Yang P, Wang X, Yang J, Yan B, Sheng H, Li Y, et al. AI-driven multiscale study on the mechanism of polygonati rhizoma in regulating immune function in STAD. ACS Omega. 2025;10(19):19770\u201396.","journal-title":"ACS Omega"},{"key":"8672_CR46","doi-asserted-by":"publisher","first-page":"1706379","DOI":"10.3389\/fimmu.2025.1706379","volume":"16","author":"T Liu","year":"2026","unstructured":"Liu T, Shang J, Wang J, Han L, Yang M, Li R, et al. Regulatory effects of traditional chinese medicine on the breast-cancer immune microenvironment. Front Immunol. 2026;16:1706379.","journal-title":"Front Immunol"},{"key":"8672_CR47","doi-asserted-by":"publisher","first-page":"1745590","DOI":"10.3389\/fphar.2026.1745590","volume":"17","author":"X Chen","year":"2026","unstructured":"Chen X, Li H, Chen J, Hou B, Tian Z, Qiu W, et al. Induction of immunogenic cell death by active components of natural products reshaping the tumor microenvironment for enhanced antitumor immunity. Front Pharmacol. 2026;17:1745590.","journal-title":"Front Pharmacol"},{"key":"8672_CR48","doi-asserted-by":"publisher","first-page":"1051998","DOI":"10.3389\/fimmu.2022.1051998","volume":"13","author":"W Zhang","year":"2022","unstructured":"Zhang W, Li S, Li C, Li T, Huang Y. Remodeling tumor microenvironment with natural products to overcome drug resistance. Front Immunol. 2022;13:1051998.","journal-title":"Front Immunol"},{"key":"8672_CR49","doi-asserted-by":"publisher","first-page":"1232456","DOI":"10.3389\/fphar.2023.1232456","volume":"14","author":"JC Chamcheu","year":"2023","unstructured":"Chamcheu JC, Ba Q, Ma H. Editorial: natural products modulate the sensitivity of cancer to anti-PD-1 based immunotherapy. Front Pharmacol. 2023;14:1232456.","journal-title":"Front Pharmacol"},{"issue":"1","key":"8672_CR50","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan X. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024;9(1):175.","journal-title":"Signal Transduct Target Ther"},{"key":"8672_CR51","doi-asserted-by":"publisher","first-page":"1147098","DOI":"10.3389\/fimmu.2023.1147098","volume":"14","author":"H Long","year":"2023","unstructured":"Long H, Wu Z. Immunoregulatory effects of huaier (trametes robiniophila murr) and relevant clinical applications. Front Immunol. 2023;14:1147098.","journal-title":"Front Immunol"},{"key":"8672_CR52","doi-asserted-by":"publisher","first-page":"123416","DOI":"10.1016\/j.carbpol.2025.123416","volume":"357","author":"L Sun","year":"2025","unstructured":"Sun L, Liu Y, Sun Q, Wang G, Du B, Liu B, et al. Polysaccharides from traditional chinese medicine and their nano-formulated delivery systems for cancer immunotherapy. Carbohydr Polym. 2025;357:123416.","journal-title":"Carbohydr Polym"},{"issue":"5","key":"8672_CR53","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3390\/ph17050636","volume":"17","author":"Z He","year":"2024","unstructured":"He Z, Liu X, Qin S, Yang Q, Na J, Xue Z, et al. Anticancer mechanism of astragalus polysaccharide and its application in cancer immunotherapy. Pharmaceuticals (Basel). 2024;17(5):636.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"8672_CR54","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","volume":"28","author":"M Smith","year":"2022","unstructured":"Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR t cell therapy. Nat Med. 2022;28(4):713\u201323.","journal-title":"Nat Med"},{"issue":"5","key":"8672_CR55","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1158\/2643-3230.BCD-24-0203","volume":"6","author":"M Uribe-Herranz","year":"2025","unstructured":"Uribe-Herranz M, Oliver-Cald\u00e9s A, Mart\u00ednez-Micaelo N, Espa\u00f1ol-Rego M, Val-Casals M, Mart\u00ednez-Soler R, et al. Microbiota shape metabolic and immune determinants of CAR-t therapy and correlate with outcomes in myeloma. Blood Cancer Discov. 2025;6(5):484\u2013504.","journal-title":"Blood Cancer Discov"},{"issue":"11","key":"8672_CR56","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/j.immuni.2022.09.014","volume":"55","author":"D Denk","year":"2022","unstructured":"Denk D, Petrocelli V, Conche C, Drachsler M, Ziegler PK, Braun A, et al. Expansion of t memory stem cells with superior anti-tumor immunity by urolithin a-induced mitophagy. Immunity. 2022;55(11):2059\u201373.","journal-title":"Immunity"},{"issue":"11","key":"8672_CR57","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1038\/s43587-025-00996-x","volume":"5","author":"D Denk","year":"2025","unstructured":"Denk D, Singh A, Kasler HG, D\u2019Amico D, Rey J, Alcober-Boquet L, et al. Effect of the mitophagy inducer urolithin a on age-related immune decline: a randomized, placebo-controlled trial. Nat Aging. 2025;5(11):2309\u201322.","journal-title":"Nat Aging"},{"key":"8672_CR58","doi-asserted-by":"publisher","first-page":"1503317","DOI":"10.3389\/fphar.2024.1503317","volume":"15","author":"V Rogovskii","year":"2025","unstructured":"Rogovskii V, Murugin VV, Vorobyev N, Popov S, Sturov N, Krasheninnikov A, et al. Urolithin a increases the natural killer activity of PBMCs in patients with prostate cancer. Front Pharmacol. 2025;15:1503317.","journal-title":"Front Pharmacol"},{"key":"8672_CR59","doi-asserted-by":"publisher","first-page":"1603018","DOI":"10.3389\/fimmu.2025.1603018","volume":"16","author":"MT El-Saadony","year":"2025","unstructured":"El-Saadony MT, Saad AM, Mohammed DM, Alkafaas SS, Ghosh S, Negm SH, et al. Curcumin, an active component of turmeric: biological activities, nutritional aspects, immunological, bioavailability, and human health benefits - a comprehensive review. Front Immunol. 2025;16:1603018.","journal-title":"Front Immunol"},{"issue":"1","key":"8672_CR60","doi-asserted-by":"publisher","first-page":"13482","DOI":"10.1038\/s41598-021-91623-3","volume":"11","author":"X Yang","year":"2021","unstructured":"Yang X, Lam W, Jiang Z, Guan F, Han X, Hu R, et al. YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment. Sci Rep. 2021;11(1):13482.","journal-title":"Sci Rep"},{"issue":"7","key":"8672_CR61","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","volume":"6","author":"L Dekker","year":"2022","unstructured":"Dekker L, Calkoen FG, Jiang Y, Blok H, Veldkamp SR, De Koning C, et al. Fludarabine exposure predicts outcome after CD19 CAR t-cell therapy in children and young adults with acute leukemia. Blood Adv. 2022;6(7):1969\u201376.","journal-title":"Blood Adv"},{"issue":"5","key":"8672_CR62","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41409-025-02539-9","volume":"60","author":"M Canelo-Vilaseca","year":"2025","unstructured":"Canelo-Vilaseca M, Sabbah M, Di Blasi R, Cristinelli C, Sureda A, Caillat-Zucman S, et al. Lymphodepletion chemotherapy in chimeric antigen receptor-engineered t (CAR-t) cell therapy in lymphoma. Bone Marrow Transpl. 2025;60(5):559\u201367.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"8672_CR63","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3390\/biomedicines12030644","volume":"12","author":"M Kond\u017ea","year":"2024","unstructured":"Kond\u017ea M, Brizi\u0107 I, Joki\u0107 S. Flavonoids as CYP3a4 inhibitors in vitro. Biomedicines. 2024;12(3):644.","journal-title":"Biomedicines"},{"key":"8672_CR64","first-page":"2174","volume":"10","author":"M Shanaida","year":"2026","unstructured":"Shanaida M, Oleshchuk O, Shevchuk O, Posokhova K, Ivankiv Y, Mocherniuk K, et al. Herbal medicines and drugs interactions: cytochrome p450 responsibility. Curr Med Chem. 2026;10:2174.","journal-title":"Curr Med Chem"},{"key":"8672_CR65","doi-asserted-by":"publisher","first-page":"1672450","DOI":"10.3389\/fphar.2025.1672450","volume":"16","author":"R Zhang","year":"2025","unstructured":"Zhang R, Yang Q, Chen Z, Huang J, Zhang G. Synergistic antitumor effects of astragalus polysaccharide: a preclinical systematic review and meta-analysis. Front Pharmacol. 2025;16:1672450.","journal-title":"Front Pharmacol"},{"key":"8672_CR66","unstructured":"Administration USFA. Considerations for the development of chimeric antigen receptor t cell products; Guidance for industry. FDA; 2024."},{"key":"8672_CR67","unstructured":"Agency EM. Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials. EMA; 2022."},{"key":"8672_CR68","first-page":"eaba1786","volume-title":"Transient rest restores functionality in exhausted CAR-t cells through epigenetic remodeling","author":"EW Weber","year":"2021","unstructured":"Weber EW, Parker KR, Sotillo E, Lynn RC, Anbunathan H, Lattin J, et al. Transient rest restores functionality in exhausted CAR-t cells through epigenetic remodeling. Science (New York, N.Y). 2021;372(6537):eaba1786."},{"key":"8672_CR69","doi-asserted-by":"publisher","first-page":"7489","DOI":"10.2147\/IJN.S527315","volume":"20","author":"X Liu","year":"2025","unstructured":"Liu X, Liu Y, Zhao D, Shan D, Guo C, Jia L. Nanomaterials mediated enhancement of CAR-t for HCC: revolutionizing immunotherapy strategies. Int J Nanomed. 2025;20:7489\u2013500.","journal-title":"Int J Nanomed"},{"issue":"2","key":"8672_CR70","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","volume":"25","author":"A Bot","year":"2026","unstructured":"Bot A, Scharenberg A, Friedman K, Guey L, Hofmeister R, Andorko JI, et al. In vivo chimeric antigen receptor (CAR)-t cell therapy. Nat Rev Drug Discov. 2026;25(2):116\u201337.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"8672_CR71","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13020-023-00785-x","volume":"18","author":"S Li","year":"2023","unstructured":"Li S, Hao L, Zhang J, Deng J, Hu X. Focus on t cell exhaustion: new advances in traditional chinese medicine in infection and cancer. Chin Med. 2023;18(1):76.","journal-title":"Chin Med"},{"key":"8672_CR72","doi-asserted-by":"publisher","first-page":"1671519","DOI":"10.3389\/fimmu.2025.1671519","volume":"16","author":"H Dong","year":"2025","unstructured":"Dong H, Song G, Wang Z, Wu X, Wang Q, Wang Y. Kaempferol as a multifaceted immunomodulator: implications for inflammation, autoimmunity, and cancer. Front Immunol. 2025;16:1671519.","journal-title":"Front Immunol"},{"key":"8672_CR73","doi-asserted-by":"publisher","first-page":"1408993","DOI":"10.3389\/fphar.2024.1408993","volume":"15","author":"J Qian","year":"2024","unstructured":"Qian J, Jiang Y, Hu H. Ginsenosides: an immunomodulator for the treatment of colorectal cancer. Front Pharmacol. 2024;15:1408993.","journal-title":"Front Pharmacol"},{"key":"8672_CR74","doi-asserted-by":"publisher","first-page":"1429483","DOI":"10.3389\/fimmu.2024.1429483","volume":"15","author":"M Guo","year":"2024","unstructured":"Guo M, Fang W, Hu Z. Traditional chinese medicine and its components effectively reduce resistance mediated by immune checkpoint inhibitors. Front Immunol. 2024;15:1429483.","journal-title":"Front Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08672-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08672-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08672-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:02:30Z","timestamp":1792425750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08672-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8672"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08672-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"31 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1314"}}